Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications

References

• Hammond SM, Caudy AA, Hannon GJ. Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet. 2001;2(2):110–119.
   PubMed Web of Science ®Google Scholar
• Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806–811. DOI:10.1038/35888.
   PubMed Web of Science ®Google Scholar
• Watts JK, Deleavey GF, Damha MJ. Chemically modified siRNA: tools and applications. Drug Discov Today. 2008;13(19–20):842–855.
   PubMed Web of Science ®Google Scholar
• Watts JK, Corey DR. Silencing disease genes in the laboratory and the clinic. J Pathol. 2012;226(2):365–379.
   PubMed Web of Science ®Google Scholar
• Agrawal N, Dasaradhi PV, Mohmmed A, et al. RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev. 2003;67(4):657–685. DOI:10.1128/MMBR.67.4.657-685.2003.
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411(6836):494–498. DOI:10.1038/35078107.
   PubMed Web of Science ®Google Scholar
• Shukla S, Sumaria CS, Pradeepkumar PI. Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook. ChemMedChem. 2010;5(3):328–349.
   PubMed Web of Science ®Google Scholar
• Filipowicz W. RNAi: the nuts and bolts of the RISC machine. Cell. 2005;122(1):17–20.
   PubMed Web of Science ®Google Scholar
• Höck J, Meister G. The Argonaute protein family. Genome Biol. 2008;9(2):210.
   PubMed Web of Science ®Google Scholar
• Hu B, Zhong L, Weng Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5(1):101. DOI:10.1038/s41392-020-0207-x.
   PubMed Web of Science ®Google Scholar
• Zogg H, Singh R, Ro S, et al. Current Advances in RNA Therapeutics for Human Diseases. Int J Mol Sci. 2022;23:2736.
   PubMed Web of Science ®Google Scholar
• Judge A, MacLachlan I. Overcoming the innate immune response to small interfering RNA. Hum Gene Ther. 2008;19(2):111–124.
   PubMed Web of Science ®Google Scholar
• Saw PE, Song EW. siRNA therapeutics: a clinical reality. Sci China Life Sci. 2020;63(4):485–500.
   PubMed Web of Science ®Google Scholar
• Johannes L, Lucchino M. Current challenges in delivery and cytosolic translocation of therapeutic RNAs. Nucleic Acid Ther. 2018;28(3):178–193.
   PubMed Web of Science ®Google Scholar
• Sajid MI, Moazzam M, Kato S, et al. Overcoming barriers for siRNA therapeutics: from bench to bedside. Pharmaceuticals (Basel). 2020;13(10):294. DOI:10.3390/ph13100294.
   PubMedGoogle Scholar
• Hammond SM, Aartsma-Rus A, Alves S, et al. Delivery of oligonucleotide-based therapeutics: challenges and opportunities. EMBO Mol Med. 2021;13(4):e13243. DOI:10.15252/emmm.202013243.
   PubMed Web of Science ®Google Scholar
• Deleavey GF, Damha MJ. Designing chemically modified oligonucleotides for targeted gene silencing. Chem Biol. 2012;19(8):937–954.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Patisiran: first global approval. Drugs. 2018;78(15):1625–1631.
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21. DOI:10.1056/NEJMoa1716153.
   PubMed Web of Science ®Google Scholar
• Akinc A, Maier MA, Manoharan M, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol. 2019;14(12):1084–1087. DOI:10.1038/s41565-019-0591-y.
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Ando Y, Dispenzeri A, et al. Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015;47(8):625–638. DOI:10.3109/07853890.2015.1068949.
   PubMed Web of Science ®Google Scholar
• Alnylam completes enrollment in APOLLO-B phase 3 study of patisiran in transthyretin-mediated (ATTR) Amyloidosis Patients with Cardiomyopathy. Available from: https://www.businesswire.com/news/home/20210601005231/en/Alnylam-Completes-Enrollment-in-APOLLO-B-Phase-3-Study-of-Patisiran-in-Transthyretin-Mediated-ATTR-Amyloidosis-Patients-with-Cardiomyopathy
   Google Scholar
• Prakash TP, Graham MJ, Yu J, et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary Nacetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 2014;42(13):8796–8807. DOI:10.1093/nar/gku531.
   PubMed Web of Science ®Google Scholar
• Springer AD, Dowdy SF. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther. 2018;28(3):109–118.
   PubMed Web of Science ®Google Scholar
• Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421–446.
   PubMed Web of Science ®Google Scholar
• Alnylam Announces U.S. Food and drug administration acceptance of new drug application for investigational vutrisiran for the treatment of the polyneuropathy of hereditary ATTR amyloidosis. Available from: https://www.businesswire.com/news/home/20210624005230/en/Alnylam-Announces-U.S.-Food-and-Drug-Administration-Acceptance-of-New-Drug-Application-for-Investigational-Vutrisiran-for-the-Treatment-of-the-Polyneuropathy-of-Hereditary-ATTR-Amyloidosis
   Google Scholar
• Alnylam completes enrollment in HELIOS-B phase 3 study of investigational vutrisiran in patients with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. Available from: https://www.businesswire.com/news/home/20210809005231/en/
   Google Scholar
• Agarwal S, Simon AR, Goel V, et al. Pharmacokinetics and pharmacodynamics of the small interfering ribonucleic acid, givosiran, in patients with acute hepatic porphyria. Clin Pharmacol Ther. 2020;108(1):63–72. DOI:10.1002/cpt.1802.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Givosiran: first approval. Drugs. 2020;80(3):335–339.
   PubMed Web of Science ®Google Scholar
• Zhang MM, Bahal R, Rasmussen TP, et al. The growth of siRNA-based therapeutics: updated clinical studies. Biochem Pharmacol. 2021;189:114432.
   PubMed Web of Science ®Google Scholar
• Debacker AJ, Voutila J, Catley M, et al. Delivery of Oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug. Mol Ther. 2020;28(8):1759–1771. DOI:10.1016/j.ymthe.2020.06.015.
   PubMed Web of Science ®Google Scholar
• Liebow A, Li X, Racie T, et al. An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria. J Am Soc Nephrol. 2017;28(2):494–503. DOI:10.1681/ASN.2016030338.
   PubMed Web of Science ®Google Scholar
• Garrelfs SF, Frishberg Y, Hulton SA, et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med. 2021;384(13):1216–1226. DOI:10.1056/NEJMoa2021712.
   PubMed Web of Science ®Google Scholar
• Alnylam reports positive topline results from ILLUMINATE-C phase 3 study of lumasiran in patients with advanced primary hyperoxaluria type 1. Available from: https://www.businesswire.com/news/home/20210729005079/en/Alnylam-Reports-Positive-Topline-Results-from-ILLUMINATE-C-Phase-3-Study-of-Lumasiran-in-Patients-with-Advanced-Primary-Hyperoxaluria-Type-1
   Google Scholar
• Taking RNAi under the skin. Available from: https://media.nature.com/original/magazine-assets/d43747-020-00189-y/d43747-020-00189-y.pdf
   Google Scholar
• Shee K, Ahn J, Hamouche F, et al. Nedosiran dramatically reduces serum oxalate in dialysis-dependent primary hyperoxaluria 1: a compassionate use case report. Urology. 2021;S0090-4295(21): 00270–3.
   Google Scholar
• Dicerna reports positive top-line results from PHYOX™2 pivotal clinical trial of nedosiran for the treatment of primary hyperoxaluria. Available from: https://www.businesswire.com/news/home/20210805006062/en/Dicerna-Reports-Positive-Top-Line-Results-From-PHYOX%E2%84%A22-Pivotal-Clinical-Trial-of-Nedosiran-for-the-Treatment-of-Primary-Hyperoxaluria
   Google Scholar
• Dicerna initiates PHYOX™4 trial of nedosiran for primary hyperoxaluria type 3. Available from: https://www.businesswire.com/news/home/20210211005286/en/Dicerna-Initiates-PHYOX%E2%84%A24-Trial-of-Nedosiran-for-Primary-Hyperoxaluriype-3
   Google Scholar
• Kosmas CE, Muñoz Estrella A, Sourlas A, et al. Inclisiran: a new promising agent in the management of hypercholesterolemia. Diseases. 2018;6(3):63. DOI:10.3390/diseases6030063.
   PubMedGoogle Scholar
• Lamb YN. Inclisiran: first approval. Drugs. 2021;81(3):389–395.
   PubMed Web of Science ®Google Scholar
• Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430–1440. DOI:10.1056/NEJMoa1615758.
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Lissitchkov T, Mamonov V, et al. Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort. J Thromb Haemost. 2021;19(6):1436–1446. DOI:10.1111/jth.15270.
   PubMed Web of Science ®Google Scholar
• Ragni MV, Georgiev P, Mant T, et al. Fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia: updated results from a phase 1 and phase 1/2 extension study in patients without inhibitors. Blood. 2016;128(22):2572. DOI:10.1182/blood.V128.22.2572.2572.
   Web of Science ®Google Scholar
• Fitusiran update following EAHAD 2021 congress. Available from: https://news.wfh.org/fitusiran-update-following-eahad-2021-congress/
   Google Scholar
• Titze-de-almeida R, David C, Titze-de-almeida SS. The race of 10 synthetic RNAi-based drugs to the pharmaceutical market. Pharm Res. 2017;34(7):1339–1363.
   PubMed Web of Science ®Google Scholar
• Thielmann M, Corteville D, Szabo G, et al. Teprasiran, A small interfering RNA, for the prevention of acute kidney injury in high-risk patients undergoing cardiac surgery: a randomized clinical study. Circulation. 2021;144(14):1133–1144.
   PubMed Web of Science ®Google Scholar
• Solano EC, Kornbrust DJ, Beaudry A, et al. Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. Nucleic Acid Ther. 2014;24(4):258–266. DOI:10.1089/nat.2014.0489.
   PubMed Web of Science ®Google Scholar
• FDA authorizes sylentis (PharmaMar Group) to initiate phase III trial with tivanisiran for the treatment of dry eye disease. Available from: https://pharmamar.com/wp-content/uploads/2021/03/PR_PhM_SYL_phase_III_tivanisiran_FDA_DEF.pdf
   Google Scholar
• Ochoa S, Milam VT. Modified nucleic acids: expanding the capabilities of functional Oligonucleotides. Molecules. 2020;25(20):4659.
   PubMed Web of Science ®Google Scholar
• Blackburn GM, Williams DM, Loakes D, et al. Nucleic acids in chemistry and biology . UK: RSC publishing; 2006. p. 143–166.
   Google Scholar
• Chernikov IV, Vlassov VV, Chernolovskaya EL. Current development of siRNA bioconjugates: from research to the clinic. Front Pharmacol. 2019;10:444.
   PubMed Web of Science ®Google Scholar
• Alshaer W, Zureigat H, Al Karaki A, et al. siRNA: mechanism of action, challenges, and therapeutic approaches. Eur J Pharmacol. 2021;905:174178.
   PubMed Web of Science ®Google Scholar
• Crooke ST, Witztum JL, Bennett CF, et al. RNA-targeted therapeutics. Cell Metab. 2018;27(4):714–739.
   PubMed Web of Science ®Google Scholar
• Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides. 2008;18(4):305–319.
   PubMed Web of Science ®Google Scholar
• Elmén J, Thonberg H, Ljungberg K, et al. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 2005;33(1):439–447. DOI:10.1093/nar/gki193.
   PubMed Web of Science ®Google Scholar
• Morita K, Hasegawa C, Kaneko M, et al. 2’-O,4’-C-ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug. Bioorg Med Chem Lett. 2002;12(1):73–76. DOI:10.1016/S0960-894X(01)00683-7.
   PubMed Web of Science ®Google Scholar
• Seth PP, Vasquez G, Allerson CA, et al. Synthesis and biophysical evaluation of 2’,4’-constrained 2’-O-methoxyethyl and 2’,4’-constrained 2’O-ethyl nucleic acid analogues. J Org Chem. 2010;75(5):1569–1581. DOI:10.1021/jo902560f.
   PubMed Web of Science ®Google Scholar
• Laursen MB, Pakula MM, Gao S, et al. Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Mol Biosyst. 2010;6(5):862–870. DOI:10.1039/b918869j.
   PubMed Web of Science ®Google Scholar
• Schlegel MK, Foster DJ, Kel’in AV, et al. Chirality dependent potency enhancement and structural impact of glycol nucleic acid modification on siRNA. J Am Chem Soc. 2017;139(25):8537–8546. DOI:10.1021/jacs.7b02694.
   PubMed Web of Science ®Google Scholar
• Langkjaer N, Pasternak A, Wengel J. UNA (unlocked nucleic acid): a flexible RNA mimic that allows engineering of nucleic acid duplex stability. Bioorg Med Chem. 2009;17(15):5420–5425.
   PubMed Web of Science ®Google Scholar
• Vaish N, Chen F, Seth S, et al. Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs. Nucleic Acids Res. 2011;39(5):1823–1832. DOI:10.1093/nar/gkq961.
   PubMed Web of Science ®Google Scholar
• Janas MM, Schlegel MK, Harbison CE, et al. Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity. Nat Commun. 2018;9(1):723. DOI:10.1038/s41467-018-02989-4.
   PubMedGoogle Scholar
• Allart B, Khan K, Rosemeyer H, et al. d-Altritol Nucleic Acids (ANA): hybridisation properties, stability, and initial structural analysis. Chem Eur J. 1999;5(8):2424–2431. DOI:10.1002/(SICI)1521-3765(19990802)5:8<2424::AID-CHEM2424>3.0.CO;2-W.
   Web of Science ®Google Scholar
• Fisher M, Abramov M, Van Aerschot A, et al. Biological effects of hexitol and altritol-modified siRNAs targeting B-Raf. Eur J Pharmacol. 2009;606(1–3):38–44. DOI:10.1016/j.ejphar.2009.01.030.
   PubMed Web of Science ®Google Scholar
• Kumar P, Degaonkar R, Guenther DC, et al. Chimeric siRNAs with chemically modified pentofuranose and hexopyranose nucleotides: altritol-nucleotide (ANA) containing GalNAc-siRNA conjugates: in vitro and in vivo RNAi activity and resistance to 5’-exonuclease. Nucleic Acids Res. 2020;48(8):4028–4040. DOI:10.1093/nar/gkaa125.
   PubMed Web of Science ®Google Scholar
• Liczner C, Duke K, Juneau G, et al. Beyond ribose and phosphate: selected nucleic acid modifications for structure-function investigations and therapeutic applications. Beilstein J Org Chem. 2021;17:908–931.
   PubMed Web of Science ®Google Scholar
• Nikam RR, Harikrishna S, Gore KR. Synthesis, structural, and conformational analysis of 4’-C-Alkyl-2’-O-Ethyl-Uridine modified nucleosides. Eur J Org Chem. 2021;6(6):924–932.
   Google Scholar
• Gore KR, Harikrishna S, Pradeepkumar PI. Influence of 2’-fluoro versus 2’-O-methyl substituent on the sugar puckering of 4’-C-aminomethyluridine. J Org Chem. 2013;78(19):9956–9962.
   PubMed Web of Science ®Google Scholar
• Nawale GN, Gore KR, Höbartner C, et al. Incorporation of 4’-C-aminomethyl-2’-O-methylthymidine into DNA by thermophilic DNA polymerases. Chem Commun (Camb). 2012;48(77):9619–9621. DOI:10.1039/c2cc35222b.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Minakawa N, Matsuda A. Synthesis and characterization of 2’-modified-4’-thioRNA: a comprehensive comparison of nuclease stability. Nucleic Acids Res. 2009;37(4):1353–1362.
   PubMed Web of Science ®Google Scholar
• Hoshika S, Minakawa N, Shionoya A, et al. Study of modification pattern-RNAi activity relationships by using siRNAs modified with 4’-thioribonucleosides. Chembiochem. 2007;8(17):2133–2138. DOI:10.1002/cbic.200700342.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Nagai C, Hatakeyama H, et al. Intracellular stability of 2’-OMe-4’-thioribonucleoside modified siRNA leads to long-term RNAi effect. Nucleic Acids Res. 2012;40(12):5787–5793. DOI:10.1093/nar/gks204.
   PubMed Web of Science ®Google Scholar
• Watts JK, Choubdar N, Sadalapure K, et al. 2’-fluoro-4’-thioarabino-modified oligonucleotides: conformational switches linked to siRNA activity. Nucleic Acids Res. 2007;35(5):1441–1451. DOI:10.1093/nar/gkl1153.
   PubMed Web of Science ®Google Scholar
• Saito Y, Hashimoto Y, Arai M, et al. Chemistry, properties, and in vitro and in vivo applications of 2’-O-methoxyethyl-4’-thioRNA, a novel hybrid type of chemically modified RNA. Chembiochem. 2014;15(17):2535–2540. DOI:10.1002/cbic.201402398.
   PubMed Web of Science ®Google Scholar
• Gore KR, Nawale GN, Harikrishna S, et al. Synthesis, gene silencing, and molecular modeling studies of 4’-C-aminomethyl-2’-O-methyl modified small interfering RNAs. J Org Chem. 2012;77(7):3233–3245. DOI:10.1021/jo202666m.
   PubMed Web of Science ®Google Scholar
• Koizumi K, Maeda Y, Kano T, et al. Synthesis of 4’-C-aminoalkyl-2’-O-methyl modified RNA and their biological properties. Bioorg Med Chem. 2018;26(12):3521–3534. DOI:10.1016/j.bmc.2018.05.025.
   PubMed Web of Science ®Google Scholar
• Kano T, Katsuragi Y, Maeda Y, et al. Synthesis and properties of 4’-C-aminoalkyl-2’-fluoro-modified RNA oligomers. Bioorg Med Chem. 2018;26(15):4574–4582. DOI:10.1016/j.bmc.2018.08.001.
   PubMed Web of Science ®Google Scholar
• Kajino R, Maeda Y, Yoshida H, et al. Synthesis and biophysical characterization of RNAs containing (R)- and (S)-5’-C-Aminopropyl-2’-O-methyluridines. J Org Chem. 2019;84(6):3388–3404. DOI:10.1021/acs.joc.8b03277.
   PubMed Web of Science ®Google Scholar
• Uematsu A, Kajino R, Maeda Y, et al. Synthesis and characterization of 4’-C-guanidinomethyl-2’-O-methyl-modified RNA oligomers. Nucleosides Nucleotides Nucleic Acids. 2020;39(1–3):280–291. DOI:10.1080/15257770.2019.1666277.
   PubMed Web of Science ®Google Scholar
• Nawale GN, Bahadorikhalili S, Sengupta P, et al. 4’-Guanidinium-modified siRNA: a molecular tool to control RNAi activity through RISC priming and selective antisense strand loading. Chem Commun (Camb). 2019;55(67):10028. DOI:10.1039/C9CC90352F.
   PubMed Web of Science ®Google Scholar
• Malek-Adamian E, Guenther DC, Matsuda S, et al. 4’-C-Methoxy-2’-deoxy-2’-fluoro modified ribonucleotides improve metabolic stability and elicit efficient RNAi-mediated gene silencing. J Am Chem Soc. 2017;139(41):14542–14555. DOI:10.1021/jacs.7b07582.
   PubMed Web of Science ®Google Scholar
• Harp JM, Guenther DC, Bisbe A, et al. Structural basis for the synergy of 4’- and 2’-modifications on siRNA nuclease resistance, thermal stability and RNAi activity. Nucleic Acids Res. 2018;46(16):8090–8104. DOI:10.1093/nar/gky703.
   PubMed Web of Science ®Google Scholar
• Malek-Adamian E, Fakhoury J, Arnold AE, et al. Effect of Sugar 2’,4’-modifications on gene silencing activity of siRNA duplexes. Nucleic Acid Ther. 2019;29(4):187–194. DOI:10.1089/nat.2019.0792.
   PubMed Web of Science ®Google Scholar
• Amarzguioui M, Holen T, Babaie E, et al. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 2003;31(2):589–595. DOI:10.1093/nar/gkg147.
   PubMed Web of Science ®Google Scholar
• Eckstein F. Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther. 2014;24(6):374–387.
   PubMed Web of Science ®Google Scholar
• Wang S, Allen N, Vickers TA, et al. Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides. Nucleic Acids Res. 2018;46(7):3579–3594. DOI:10.1093/nar/gky145.
   PubMed Web of Science ®Google Scholar
• Parmar R, Willoughby JL, Liu J, et al. 5’-(E)-Vinylphosphonate: a stable phosphate mimic can improve the RNAi activity of siRNA-GalNAc conjugates. Chembiochem. 2016;17(11):985–989. DOI:10.1002/cbic.201600130.
   PubMed Web of Science ®Google Scholar
• Elkayam E, Parmar R, Brown CR, et al. siRNA carrying an (E)-vinylphosphonate moiety at the 5΄ end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2. Nucleic Acids Res. 2017;45(6):3528–3536. DOI:10.1093/nar/gkw1171.
   PubMed Web of Science ®Google Scholar
• Parmar RG, Brown CR, Matsuda S, et al. Facile synthesis, geometry, and 2’-substituent-dependent in vivo activity of 5’-(E)- and 5’-(Z)-Vinylphosphonate-modified siRNA conjugates. J Med Chem. 2018;61(3):734–744. DOI:10.1021/acs.jmedchem.7b01147.
   PubMed Web of Science ®Google Scholar
• Prakash TP, Kinberger GA, Murray HM, et al. Synergistic effect of phosphorothioate, 5’-vinylphosphonate and GalNAc modifications for enhancing activity of synthetic siRNA. Bioorg Med Chem Lett. 2016;26(12):2817–2820. DOI:10.1016/j.bmcl.2016.04.063.
   PubMed Web of Science ®Google Scholar
• Haraszti RA, Roux L, Coles AH, et al. 5΄-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo. Nucleic Acids Res. 2017;45(13):7581–7592. DOI:10.1093/nar/gkx507.
   PubMed Web of Science ®Google Scholar
• Lima WF, Prakash TP, Murray HM, et al. Single-stranded siRNAs activate RNAi in animals. Cell. 2012;150(5):883–894. DOI:10.1016/j.cell.2012.08.014.
   PubMed Web of Science ®Google Scholar
• Prakash TP, Lima WF, Murray HM, et al. Identification of metabolically stable 5’-phosphate analogs that support single-stranded siRNA activity. Nucleic Acids Res. 2015;43(6):2993–3011. DOI:10.1093/nar/gkv162.
   PubMed Web of Science ®Google Scholar
• Altmann KH, Kesselring R, Francotte E, et al. 4,6-Methano carbocyclic thymidine: a conformationally constrained building block for oligonucleotides. Tetrahedron Lett. 1994;35(15):2331–2334. DOI:10.1016/0040-4039(94)85212-X.
   Web of Science ®Google Scholar
• Jung ME, Dwight TA, Vigant F, et al. Synthesis and duplex-stabilizing properties of fluorinated N-methanocarbathymidine analogues locked in the C3’-endo conformation. Angew Chem Int Ed Engl. 2014;53:9893–9897.
   PubMed Web of Science ®Google Scholar
• Akabane-Nakata M, Kumar P, Das RS, et al. Synthesis and biophysical characterization of RNAs containing 2’-Fluorinated Northern Methanocarbacyclic nucleotides. Org Lett. 2019;21(7):1963–1967. DOI:10.1021/acs.orglett.8b04153.
   PubMed Web of Science ®Google Scholar
• Akabane-Nakata M, Erande ND, Kumar P, et al. siRNAs containing 2’-fluorinated Northern-methanocarbacyclic (2’-F-NMC) nucleotides: in vitro and in vivo RNAi activity and inability of mitochondrial polymerases to incorporate 2’-F-NMC NTPs. Nucleic Acids Res. 2021;49(5):2435–2449. DOI:10.1093/nar/gkab050.
   PubMed Web of Science ®Google Scholar